Adjuvant medical treatment of malignant melanoma;Adjuvante medikamentöse therapie des malignen melanoms

Onkologe

Volumn 10, Issue 7, 2004, Pages 710-716

  Volkenandt, M ^a   Hauschild, A ^b   Garbe, C ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Adjuvant therapy; Chemotherapy; IFN ; Immunotherapy; Melanoma

Indexed keywords

BCG VACCINE; DACARBAZINE; IMMUNOMODULATING AGENT; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CLINICAL RESEARCH; CONTROLLED STUDY; EVALUATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; OPTIMAL DRUG DOSE; PROSPECTIVE STUDY; RANDOMIZATION; REVIEW; STATISTICAL SIGNIFICANCE;

EID: 4344566914     PISSN: 09478965     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00761-004-0721-4     Document Type: Review

References (29)

1. Beiteke U, Ruppert P, Garbe C et al. (1993) Adjuvante Therapie des primären malignen Melanoms mit natürlichem humanem Interferon beta. Hautarzt 44:365-371
2. Cameron DA, Cornbleet MC, MacKie RM, Hunter JA, Gore M, Hancock B, Smyth JF (2001) Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer 84:1146-1149
3. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A (2001) Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 358:866-869
4. Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RMJ, Kugler J, Rodrigue U (1995) Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13:2776-2783
5. Czarnetzki BM, Macher E, Suciu S, Thomas D, Steerenberg PA, Rumke P (1993) Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non - treatment in a randomized multicenter study (EORTC protocol 18781). Eur J Cancer 29A:1237-1242
6. Dummer R, Hauschild A, Henseler T, Burg G (1998) Combined interferon-alpha and interleukin-2 adjuvant treatment for melanoma. Lancet 352.908-909
7. th Annual meeting, 2001 Educational Book, pp 88-93
8. Garbe C, Kapp A, Hauschild A, Djawari D, Reinhold D, Linse R, Elsner P (2002) Adjuvant treatment of patients with cutaneous melanoma and completely resected metastasis with vindesine versus observation alone. Preliminary evaluation of a randomised multicenter DeCOG Trial. Melanoma Res 12:A12-A13
9. Garbe C, Hauschild A, Linse R et al. (2002) Adjuvant treatment of patients with cutaneous melanoma and regional node metastasis with low dose interferon- or interferon- plus DTIC versus observation alone. Preliminary evaluation of a randomised multicenter DeCOG trial. Melanoma Res 12:A13-A14
10. Grob JJ, Dreno B, de la Salmoniere P et al. (1998) Randomised trail of interferon alpha-2b as adjuvant therapy in resected primary melanoma thicker than 1.S mm without clinically detectable node metastases. Lancet 351:1905-1910
11. Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M (2004) Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 22:53-61
12. Hauschild A, Volkenandt M, Garbe C (2000) Adjuvante medikamentöse Therapie des malignen Melanoms. Aktueller Wissensstand und derzeitige Multicenterstudien in den deutschsprachigen Ländern. Dtsch Med Wochenschr 125:1272-1278
13. Hauschild A, Weichenthal M, Balda BR et al. (2003) Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinical detectable node metastasis. J Clin Oncol 21:2883-2888
14. Hill GJ, Moss SE, Golomb FM et al. (1981) DTIC and combination therapy for melanoma, III: DTIC Surgical Adjuvant Study COG protocol 7040. Cancer 47:2556-2562
15. Karg C, Garbe C, Orfanos CE (1990) Chemotherapie des malignen Melanoms - aktueller Stand. Hautarzt 41:56-65
16. Kirkwood JM, Strawderman MH, Ernstoff MS et al. (1996) Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma. The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17
17. Kirkwood J, Agarwala SS (1998) Adjuvant systemic therapy. In: Balch CM, Houghton AN, Sober AJ, Soong S (eds) Cutaneous melanoma. Quality Medical Publishing, St. Louis: 451-459
18. Kirkwood JM, Ibrahim JG, Sondak VK et al. (2000) High- and low-dose interferon alfa-2b in high risk melanoma: first analysis of intergroup trial E 1690. J Clin Oncol 18:2444-2458
19. Kirkwood JM, Ibrahim JG, Sosman JA et al. (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/Q5-21 vaccine in patients with resected stage IIb-III melanoma: results of intergroup trial E1694. J Clin Oncol 19:2370-2380
20. Kleeberg UR, Sudu S, Brocker EB et al. (2004) Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. RIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3mm) or regional lymph node metastasis. Eur J Cancer 40:390-402
21. Koops HS, Vaglini M, Suciu S et al. (1998) Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial. J Clin Oncol 16:2906-2912
22. Lens MB, Dawes M (2002) Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 20:1818-1825
23. Meyskens FL, Kopecky K, Samson M et al. (1990) Recombinant human interferon gamma: Adverse effects in high-risk stage I and II cutaenous malignant melanoma. J Natl. Cancer Inst 82:1071
24. Pehamberger H, Soyer HP, Steiner A et al. (1998) Adjuvant interferon-alpha2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 16:1425-1429
25. Retsas S, Quigley M, Pectasides D et al. (1994) Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival. Cancer 73:2119-2130
26. Spitler LE, Grossbard ML, Ernsthoff MS et al.(2000) Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony stimulating factor. J Clin Oncol 18:1614-1621
27. Veronesi U, Adamus J, Aubert C (1982) A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 307:913-916
28. Volkenandt M, Schmidt M, Konz B et al. (1999) Klinisch-epidemiologische Daten von Patienten mit malignen Melanomen aus dem Bereich des Tumorzentrums München von 1977-1997. Hautarzt 50:470-478
29. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suici S (2003) Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rep 29:241-252